Trials / Completed
CompletedNCT01984736
EVP-6124 Hepatic Impairment Study
A Multi-Center, Open-Label Phase I Study to Investigate the Effect of Different Degrees of Hepatic Impairment on the Single-Dose Pharmacokinetics of EVP-6124 in Patients With Hepatic Impairment Compared to Subjects With Normal Hepatic Function
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 34 (actual)
- Sponsor
- FORUM Pharmaceuticals Inc · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the pharmacokinetics of EVP-6124 and metabolites after a single oral dose in subjects with mild, moderate and severe hepatic impairment compared with subjects with normal hepatic function.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Experimental: EVP-6124 |
Timeline
- Start date
- 2013-06-01
- Primary completion
- 2014-12-01
- First posted
- 2013-11-15
- Last updated
- 2015-01-15
Locations
3 sites across 3 countries: Czechia, Poland, Slovakia
Source: ClinicalTrials.gov record NCT01984736. Inclusion in this directory is not an endorsement.